Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer

Jae Il Roh, Young Hoon Sung, Han Woong Lee

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Telomerase is responsible for maintaining the length of telomeres at the ends of chromosomes. Although most somatic cells do not exhibit telomerase activity, it is reactivated in approximately 85% of cancers. This simple and attractive phenomenon steers the development of anticancer drugs targeting telomeres and telomerase. Recent studies have been revealing extratelomeric roles of telomerase in normal tissues, affecting processes that are critical for survival and aging of organisms. In this review, we will discuss the current therapeutic strategies targeting telomeres and telomerase and evaluate their potential advantages and risks with respect to nontelomeric functions.

Original languageEnglish
Pages (from-to)1161-1166
Number of pages6
JournalOncoTargets and Therapy
Volume6
DOIs
Publication statusPublished - 2013 Sep 5

Fingerprint

Telomerase
Telomere
Pharmaceutical Preparations
Neoplasms
Drug Delivery Systems
Chromosomes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

@article{c809b9d43af84454bfd14cccfb2eb9a3,
title = "Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer",
abstract = "Telomerase is responsible for maintaining the length of telomeres at the ends of chromosomes. Although most somatic cells do not exhibit telomerase activity, it is reactivated in approximately 85{\%} of cancers. This simple and attractive phenomenon steers the development of anticancer drugs targeting telomeres and telomerase. Recent studies have been revealing extratelomeric roles of telomerase in normal tissues, affecting processes that are critical for survival and aging of organisms. In this review, we will discuss the current therapeutic strategies targeting telomeres and telomerase and evaluate their potential advantages and risks with respect to nontelomeric functions.",
author = "Roh, {Jae Il} and Sung, {Young Hoon} and Lee, {Han Woong}",
year = "2013",
month = "9",
day = "5",
doi = "10.2147/OTT.S50918",
language = "English",
volume = "6",
pages = "1161--1166",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer. / Roh, Jae Il; Sung, Young Hoon; Lee, Han Woong.

In: OncoTargets and Therapy, Vol. 6, 05.09.2013, p. 1161-1166.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer

AU - Roh, Jae Il

AU - Sung, Young Hoon

AU - Lee, Han Woong

PY - 2013/9/5

Y1 - 2013/9/5

N2 - Telomerase is responsible for maintaining the length of telomeres at the ends of chromosomes. Although most somatic cells do not exhibit telomerase activity, it is reactivated in approximately 85% of cancers. This simple and attractive phenomenon steers the development of anticancer drugs targeting telomeres and telomerase. Recent studies have been revealing extratelomeric roles of telomerase in normal tissues, affecting processes that are critical for survival and aging of organisms. In this review, we will discuss the current therapeutic strategies targeting telomeres and telomerase and evaluate their potential advantages and risks with respect to nontelomeric functions.

AB - Telomerase is responsible for maintaining the length of telomeres at the ends of chromosomes. Although most somatic cells do not exhibit telomerase activity, it is reactivated in approximately 85% of cancers. This simple and attractive phenomenon steers the development of anticancer drugs targeting telomeres and telomerase. Recent studies have been revealing extratelomeric roles of telomerase in normal tissues, affecting processes that are critical for survival and aging of organisms. In this review, we will discuss the current therapeutic strategies targeting telomeres and telomerase and evaluate their potential advantages and risks with respect to nontelomeric functions.

UR - http://www.scopus.com/inward/record.url?scp=84883272144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883272144&partnerID=8YFLogxK

U2 - 10.2147/OTT.S50918

DO - 10.2147/OTT.S50918

M3 - Review article

VL - 6

SP - 1161

EP - 1166

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -